PCM
GILD icon

Portolan Capital Management’s Gilead Sciences GILD Stock Holding History

Portolan Capital Management’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-38,592
Closed -$2.97M – 147
2020
Q2 		$2.97M Sell
38,592
-161,746
-81% -$12.4M 0.34% 95
2020
Q1 		$15M Buy
+200,338
New +$13.8M 2.25% 11

Other funds holding GILD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM

Portolan Capital Management's GILD Position: Q3 2020 in Review

Portolan Capital Management sold out of Gilead Sciences (GILD) in Q3 2020, closing a stake of 38,592 shares — an estimated $2.97M sold.

Portolan Capital Management first reported a position in GILD in Q1 2020 and held it in 2 quarters. The position peaked at $15M in Q1 2020. 1,538 funds tracked by Wall St. Rank hold GILD as of Q3 2020.

  • Portolan Capital Management reported no remaining Gilead Sciences position as of Q3 2020 after selling out during the quarter.
  • Portolan Capital Management sold 38,592 Gilead Sciences shares in Q3 2020, an estimated $2.97M.
  • Portolan Capital Management first reported a position in Gilead Sciences in Q1 2020 and held it in 2 quarters.
  • Portolan Capital Management's Gilead Sciences position peaked at $15M in Q1 2020.
  • 1,538 funds tracked by Wall St. Rank held Gilead Sciences as of Q3 2020.

Based on Portolan Capital Management's 13F filing for Q3 2020, filed 16 Nov 2020.